Evidence map›Paper›PMID 20807771›Full record

ArticleThe Journal of biological chemistry2010

Identification of an endothelin-converting enzyme-2-specific fluorigenic substrate and development of an in vitro and ex vivo enzymatic assay.

Tanja Ouimet, Sou-Vinh Orng, Hervé Poras, Khatuna Gagnidze, Lakshmi A Devi, Marie-Claude Fournié-Zaluski, Bernard P Roques

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Neprilysin Inhibitors and Bradykinin.Frontiers in medicine · 2018
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Tanja OuimetPharmaleads, Paris BioPark, 75013 Paris, France.
Sou-Vinh Orng
Hervé Poras
Khatuna Gagnidze
Lakshmi A Devi
Marie-Claude Fournié-Zaluski
Bernard P Roques
Pharmaleads (France) · FRIcahn School of Medicine at Mount Sinai · US

Funding

Enzymes Involved in Neuropeptide Biosynthesis, Processing and RegulationR01NS026880 · NINDS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI DEVI, LAKSHMI A · 1994 to 2019
$6.5M
POST-TRANSLATIONAL REGULATION OF OPIOID RECEPTORSK05DA019521 · NIDA · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI DEVI, LAKSHMI A · 2005 to 2014
$1.2M
NIDA NIH HHS K05 DA019521NINDS NIH HHS R01 NS026880
6 · The paper itself

Abstract

Endothelin-converting enzyme-2 (ECE-2) is a membrane-bound zinc-dependent metalloprotease that shares a high degree of sequence homology with ECE-1, but displays an acidic pH optimum characteristic of maturing enzymes acting late in the secretory pathway. Although ECE-2, like ECE-1, can cleave the big endothelin intermediate to produce the vasoconstrictive endothelin peptide, its true physiological function remains to be elucidated, a task that is hampered by the lack of specific tools to study and discriminate ECE-2 from ECE-1, i.e. specific substrates and/or specific inhibitors. To fill this gap, we searched for novel ECE-specific peptide substrates. To this end, peptides derived from the big endothelin intermediate were tested using ECE-1 and ECE-2, leading to the identification of an ECE-1-specific substrate. Moreover, screening of our proprietary fluorigenic peptide Fluofast® libraries using ECE-1 and ECE-2 allowed the identification of Ac-SKG-Pya-F-W-Nop-GGK-NH(2) (PL405), as a specific and high affinity ECE-2 substrate. Indeed, ECE-2 cleaved PL405 at the Pya-F amide bond with a specificity constant (k(cat)/K(m)) of 8.1 ± 0.9 × 10(3) M(-1) s(-1). Using this novel substrate, we also characterized the first potent (K(i) = 7.7 ± 0.3 nM) and relatively selective ECE-2 inhibitor and developed a quantitative fluorigenic ECE-2 assay. The assay was used to study the ex vivo ECE-2 activity in wild type and ECE-2 knock-out tissues and was found to truly reflect ECE-2 expression patterns. The PL405 assay is thus the first tool to study ECE-2 inhibition using high throughput screening or for ex vivo ECE-2 quantification.

Indexed as

AnimalsAspartic Acid EndopeptidasesEndothelin-Converting EnzymesEndothelinsEnzyme AssaysEnzyme InhibitorsFluorescent DyesGene Expression Regulation, EnzymologicHumansMetalloendopeptidasesMiceOrgan SpecificityPeptide LibraryPeptidesSubstrate SpecificityAspartic Acid EndopeptidasesECE1 protein, humanEce1 protein, mouseECE2 protein, humanEce2 protein, mouseEndothelin-Converting EnzymesEndothelinsEnzyme InhibitorsFluorescent DyesMetalloendopeptidasesPeptide LibraryPeptides

Identifiers

PMID20807771
PMCPMC2966053
OpenAlexW2032161953

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.